The PennZone

PITTSBURGH, Oct. 24, 2022 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) will announce financial results for the third quarter of 2022 on Monday, November 7, 2022. Executive Chairman Robert J. Coury, Chief Executive Officer Michael Goettler, President Rajiv Malik, and Chief Financial Officer Sanjeev Narula will host a webcast at 8:30 a.m. ET on the same date to review the quarterly results and provide an update on the company's February 28 Investor Event.

More on The PennZone

• Integris Composites Joins International Sea Power Conference Aboard HMS Prince of Wales
• Commercial Sales Launch Following FDA Approval; National Sales Force Now in Action as January Shipments and Major Market Opportunity Take Shape
• ViewDNS.info Launches Monitors, Alerting Teams the Moment Something Changes on Their Domains
• Philadelphia-Area Entrepreneur Nouho M Kanneh Builds $37 Million Net Worth Across Real Estate, E-Commerce and Retail
• Meals on Wheels of the Greater Lehigh Valley Raises Over $50,000 to Help Feed Local Seniors

Investors and the general public are invited to listen to a live webcast of the call at investor.viatris.com or by calling 800.225.9448 or 203.518.9708 for international callers (Conference ID: VTRSQ322).  A replay of the webcast also will be available on the website.

About Viatris
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company empowering people worldwide to live healthier at every stage of life. We provide access to medicines, advance sustainable operations, develop innovative solutions and leverage our collective expertise to connect more people to more products and services through our one-of-a-kind Global Healthcare Gateway®. Formed in November 2020, Viatris brings together scientific, manufacturing and distribution expertise with proven regulatory, medical, and commercial capabilities to deliver high-quality medicines to patients in more than 165 countries and territories. Viatris' portfolio comprises more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both non-communicable and infectious diseases, including globally recognized brands, complex generic and branded medicines, a portfolio of biosimilars and a variety of over-the-counter consumer products. With approximately 37,000 colleagues globally, Viatris is headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India. Learn more at viatris.com and investor.viatris.com, and connect with us on Twitter at @ViatrisInc, LinkedIn and YouTube.

More on The PennZone

• Contracting Resources Group Named a 2027 Elev8 GovCon Honoree by OrangeSlices
• Malcolm Hill: The Laughter, Legacy and Determination Behind a Philly Comedy Mainstay
• The World's No.1 Superstar® Brings Christmas Back in Grand Style with Music, Cinematic Glamour, and Luxury Fashion
• New Six-Figure Media Agreement Builds Powerful Momentum, Expanding Government Contracts, FBI Access and Growing AI Recognition: Cyabra (NAS DAQ: CYAB)
• Christmas Beats Summer in Paris: Travel Photoshoots Peak on Dec. 30

SOURCE Viatris Inc.

---

Show All News | Disclaimer | Report Violation